Tanespimycin: all 51 studies that test it

Page 1 of 1. Open to participants first (0), then studies with results posted, then the rest; newest registration first within each.

• IPI-504 in NSCLC Patients With ALK TranslocationsTerminatedNCT01228435Phase 2Results posted
• Gemcitabine Hydrochloride and Tanespimycin in Treating Patients With Stage IV Pancreatic CancerCompletedNCT00577889Phase 2Results posted
• Tanespimycin in Treating Patients With Inoperable Locoregionally Advanced or Metastatic Thyroid CancerCompletedNCT00118248Phase 2Results posted
• 17-AAG in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Previous Hormone TherapyCompletedNCT00118092Phase 2Results posted
• 17-AAG in Treating Patients With Relapsed or Refractory Anaplastic Large Cell Lymphoma, Mantle Cell Lymphoma, or Hodgkin's LymphomaCompletedNCT00117988Phase 2Results posted
• Tanespimycin in Treating Women With Refractory Locally Advanced or Metastatic Breast CancerTerminatedNCT00096109Phase 2Results posted
• Gemcitabine Hydrochloride and Tanespimycin in Treating Patients With Recurrent Advanced Ovarian Epithelial or Peritoneal Cavity CancerCompletedNCT00093496Phase 2Results posted
• 17AAG to Treat Kidney Tumors in Von Hippel-Lindau DiseaseCompletedNCT00088374Phase 2Results posted
• Phase 1b/2 Study of Retaspimycin HCl (IPI-504) in Combination With Everolimus in KRAS Mutant Non-small Cell Lung CancerCompletedNCT01427946Phase 1/2
• A Double-blind Study Evaluating IPI-504 and Docetaxel in Patients With Non-Small Cell Lung CancerCompletedNCT01362400Phase 2
• Dose Escalation of IPI-493 in Hematologic MalignanciesTerminatedNCT01193491Phase 1
• Study Evaluating the Efficacy and Safety of IPI 504 in Patients With Advanced Dedifferentiated LiposarcomaWithdrawnNCT00969917Phase 2
• Efficacy and Safety of IPI-504 With Trastuzumab Pretreated, Locally Advanced or Metastatic HER2 Positive Breast CancerTerminatedNCT00817362Phase 2
• Clinical Trial of Continuing Treatment for Patients Who Have Participated on a Prior Protocol Investigating TanespimycinCompletedNCT00779428Phase 2
• Clinical Trial of the Combination of Trastuzumab (Herceptin) and Tanespimycin in Patients With Solid Tumors and Her2 Positive Metastatic Breast Cancer That Have Previously Failed HerceptinCompletedNCT00773344Phase 1/2
• A Phase 1 Dose Escalation Study of IPI-493TerminatedNCT00724425Phase 1
• Study Evaluating IPI-504 in Patients With Gastrointestinal Stromal Tumors (GIST) Following Failure of at Least Imatinib and SunitinibTerminatedNCT00688766Phase 3
• A Study to Evaluate the Antitumor Activity and Safety of IPI-504 in Patients With Advanced Breast CancerWithdrawnNCT00627627Phase 1/2
• A Study Evaluating the Safety and Antitumor Activity of IPI-504, in Patients With Metastatic MelanomaTerminatedNCT00627419Phase 2
• Phase I Study of IPI-504 and Docetaxel in Patients With Advanced Solid TumorsCompletedNCT00606814Phase 1
• A Phase 2 Study to Investigate the Clinical Activity of IPI-504 in Patients With Hormone-resistant Prostate CancerCompletedNCT00564928Phase 2
• A Study of Tanespimycin (KOS-953) in Patients With Multiple Myeloma in First RelapseCompletedNCT00546780Phase 3
• A Study of Tanespimycin (KOS-953) in Patients With Relapsed-refractory Multiple MyelomaCompletedNCT00514371Phase 2/3
• Phase I/II Safety Study of IPI-504 in Relapsed/Refractory Stage IIIb, or Stage IV Non-small Cell Lung Cancer (NSCLC)CompletedNCT00431015Phase 1/2
• PXD101 and 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Metastatic or Unresectable Solid Tumors or LymphomaTerminatedNCT00354185Phase 1
• Phase 1, Dose-Escalation, Pharmacodynamic Study of IV CNF1010 in ZAP-70 Positive CLLTerminatedNCT00319930Phase 1
• Sorafenib and Bortezomib in Treating Patients With Advanced CancerCompletedNCT00303797Phase 1
• Safety Study of IPI-504 in Patients With Gastrointestinal Stromal Tumors (GIST) or Soft Tissue Sarcomas (STS)CompletedNCT00276302Phase 1
• 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Systemic MastocytosisCompletedNCT00132015Phase 2
• 17-AAG and Sorafenib in Treating Patients With Unresectable or Metastatic Solid TumorsCompletedNCT00121264Phase 1
• 17-AAG and Irinotecan in Treating Patients With Locally Advanced or Metastatic Solid TumorsCompletedNCT00119236Phase 1
• Safety Study of IPI-504 in Patients With Relapsed and Relapsed Refractory Multiple MyelomaCompletedNCT00113204Phase 1
• 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Metastatic Malignant MelanomaCompletedNCT00104897Phase 2
• 17-N-Allylamino-17-Demethoxygeldanamycin and Bortezomib in Treating Patients With Relapsed or Refractory Hematologic CancerTerminatedNCT00103272Phase 1
• 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia That Did Not Respond to Imatinib MesylateCompletedNCT00100997Phase 1
• 17-N-Allylamino-17-Demethoxygeldanamycin With or Without Rituximab in Treating Patients With Relapsed B-Cell Chronic Lymphocytic Leukemia or Prolymphocytic LeukemiaTerminatedNCT00098488Phase 1
• Tanespimycin and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, Chronic Myelomonocytic Leukemia, or Myelodysplastic SyndromesCompletedNCT00098423Phase 1
• Tanespimycin and Bortezomib in Treating Patients With Advanced Solid Tumors or LymphomasTerminatedNCT00096005Phase 1
• Tanespimycin in Treating Young Patients With Recurrent or Refractory Leukemia or Solid TumorsCompletedNCT00093821Phase 1
• 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Metastatic Kidney CancerCompletedNCT00093405Phase 2
• Tanespimycin in Treating Patients With Stage III-IV MelanomaTerminatedNCT00087386Phase 2
• 17-N-Allylamino-17-Demethoxygeldanamycin and Paclitaxel in Treating Patients With Metastatic or Unresectable Solid TumorCompletedNCT00087217Phase 1
• Bortezomib in Treating Patients With Relapsed or Refractory Hodgkin's LymphomaCompletedNCT00082966Phase 2
• 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Young Patients With Relapsed or Refractory Solid Tumors or LeukemiaCompletedNCT00079404Phase 1
• Combination Chemotherapy in Treating Patients With Metastatic or Unresectable Solid TumorsCompletedNCT00058253Phase 1
• Tanespimycin, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Advanced Solid TumorsCompletedNCT00047047Phase 1
• Geldanamycin Analogue in Treating Patients With Advanced Solid Tumors or Non-Hodgkin's LymphomaTerminatedNCT00019708Phase 1
• 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Advanced Epithelial Cancer, Malignant Lymphoma, or SarcomaCompletedNCT00004241Phase 1
• 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Solid Tumors That Cannot Be Removed By SurgeryCompletedNCT00004075Phase 1
• Chemotherapy in Treating Patients With Refractory Advanced Solid Tumors or Hematologic CancerCompletedNCT00004065Phase 1
• Geldanamycin Analogue in Treating Patients With Advanced CancerCompletedNCT00003969Phase 1

← Tanespimycin overview